Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination.
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study.
Reactive astrocytes as therapeutic targets for CNS disorders.
Immunomodulatory effects of Vitamin D in multiple sclerosis.
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence.
Optimizing IFN Beta - 1B Dose (Optims)
Multiple sclerosis.
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multipl
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications
A molecular link between the active component of marijuana and Alzheimer's disease pathology.
Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase.
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.
Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand.
Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis

Pages